Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives.

EQ-5D FACT-P QLQ-C30 health-related quality of life metastatic prostate cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 Dec 2021
Historique:
received: 03 12 2021
revised: 22 12 2021
accepted: 25 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 12 1 2022
Statut: epublish

Résumé

With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.

Identifiants

pubmed: 35008310
pii: cancers14010147
doi: 10.3390/cancers14010147
pmc: PMC8749907
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Lancet Oncol. 2018 Oct;19(10):1404-1416
pubmed: 30213449
Cancer Med. 2020 Jun;9(12):4039-4058
pubmed: 32333639
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
JMIR Mhealth Uhealth. 2018 Feb 20;6(2):e45
pubmed: 29463489
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
Eur J Cancer. 2008 Nov;44(16):2418-24
pubmed: 18774706
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Qual Life Res. 2013 Dec;22(10):2685-91
pubmed: 23532341
Eur J Cancer. 2021 Sep;154:138-146
pubmed: 34273811
Qual Life Res. 2015 Mar;24(3):591-8
pubmed: 25326871
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Value Health. 2014 Mar;17(2):238-44
pubmed: 24636382
Ann Oncol. 2015 Jan;26(1):179-185
pubmed: 25361992
Eur Urol. 2020 Oct;78(4):603-614
pubmed: 32336645
Lancet Oncol. 2013 Nov;14(12):1193-9
pubmed: 24075621
Urology. 1997 Dec;50(6):920-8
pubmed: 9426724
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Eur J Cancer. 2013 Nov;49(17):3648-57
pubmed: 23973186
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Recent Results Cancer Res. 1988;111:231-49
pubmed: 2459750
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Lancet Oncol. 2018 Feb;19(2):194-206
pubmed: 29326030
Lancet Oncol. 2019 Apr;20(4):556-569
pubmed: 30770294
Value Health. 2012 Mar-Apr;15(2):305-11
pubmed: 22433762
J Clin Epidemiol. 1997 Apr;50(4):441-50
pubmed: 9179103
Eur Urol Focus. 2021 Jul;7(4):742-751
pubmed: 32089495
Lancet Oncol. 2019 Nov;20(11):1518-1530
pubmed: 31578173
Eur J Cancer. 2012 Jul;48(11):1713-21
pubmed: 22418017
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
J Clin Oncol. 2017 Oct 1;35(28):3189-3197
pubmed: 28753384
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Support Care Cancer. 2014 Aug;22(8):2151-60
pubmed: 24652051
Eur Urol. 2020 Sep;78(3):481-482
pubmed: 32636097
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Eur J Cancer. 2001 Jul;37(11):1331-4
pubmed: 11435060
J Clin Oncol. 2018 Apr 10;36(11):1088-1095
pubmed: 29522362
Qual Life Res. 2010 Aug;19(6):875-86
pubmed: 20405245
Health Qual Life Outcomes. 2017 Jun 23;15(1):130
pubmed: 28645287

Auteurs

Alexander Kretschmer (A)

Department of Urology, Ludwig-Maximilians University, 81377 Munich, Germany.

Roderick C N van den Bergh (RCN)

Department of Urology, Antonius Hospital, 3543 AZ Utrecht, The Netherlands.

Alberto Martini (A)

Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

Giancarlo Marra (G)

Department of Urology, San Giovanni Battista Hospital, University of Torino, 10126 Torino, Italy.

Massimo Valerio (M)

Department of Urology, CHUV Lausanne, 1011 Lausanne, Switzerland.

Igor Tsaur (I)

Department of Urology and Pediatric Urology, Mainz University Medicine, 55131 Mainz, Germany.

Isabel Heidegger (I)

Department of Urology, Medical University Innsbruck, 6020 Innsbruck, Austria.

Veeru Kasivisvanathan (V)

Division of Surgery and Interventional Science, University College London, London W1W 7TY, UK.

Claudia Kesch (C)

Department of Urology, University Hospital Essen, 45147 Essen, Germany.

Felix Preisser (F)

Department of Urology, University Hospital Frankfurt, 60590 Frankfurt, Germany.

Christian D Fankhauser (CD)

Luzerner Kantonsspital, 6000 Lucerne, Switzerland.

Fabio Zattoni (F)

Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy.
Urology Unit, Academical Medical Centre Hospital, 33100 Udine, Italy.

Francesco Ceci (F)

Division of Nuclear Medicine, IEO European Institute of Oncology, 20141 Milan, Italy.

Jonathan Olivier (J)

Department of Urology, Lille University Hospital, 59000 Lille, France.

Peter Chiu (P)

SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.

Ignacio Puche-Sanz (I)

Department of Urology, Bio-Health Research Institute, Hospital Universitario Virgen de las Nieves, University of Granada, 18014 Granada, Spain.

Constance Thibault (C)

Department of Medical Oncology, European Georges Pompidou Hospital, Assistance Publique des Hôpitaux de Paris, Paris Descartes University, 75004 Paris, France.

Giorgio Gandaglia (G)

Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
Department of Urology, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
Department of Urology, Koc University Hospital, 34010 Istanbul, Turkey.

Classifications MeSH